Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Michael X. Repka, MD, MBA, on building consensus and future directions
In advance of the upcoming CCOI Myopia Workshop, scheduled for September 8 in Paris, France, Michael X. Repka, MD, MBA—program co-chair of the event and current president of the American Academy of Ophthalmology—spoke about the challenges and opportunities facing the…
First patient dosed in Qlaris Bio’s phase 2 Nightingale clinical trial for QLS-111
(Image Credit: AdobeStock) The first patient has been dosed in Qlaris Bio’s Phase II Nightingale clinical trial for QLS-111 in patients with normal tension glaucoma (NTG).1 The study, which is Qlaris Bio’s third phase 2 clinical trial of the company’s…
OCT changes with low-level red light therapy for myopia in children
(Image credit: AdobeStock/Microgen) Zhehuan Zhang, MD, and colleagues from the Department of Ophthalmology, Children’s Hospital of Fudan University, National Children’s Medical Center, Shanghai, emphasized the importance of patients undergoing routine optical coherence tomography (OCT) scans during repeated low-level red-light (RLRL)…
Aflibercept 8 mg Shows Long-Term Efficacy in Diabetic Macular Edema with Fewer Injections, shows trial – Medical Dialogues
Aflibercept 8 mg Shows Long-Term Efficacy in Diabetic Macular Edema with Fewer Injections, shows trial Medical Dialogues Source: Author: | Date: 2025-08-26 15:00:00 Source: Author: | Date: 2025-08-26 15:00:00
The potential of AI in retina with Daniela Ferrara
This conversation features Daniella Ferrara, Chief Medical Officer for TopCon Healthcare, discussing the transformative potential of artificial intelligence in retinal imaging and ophthalmology. Ferrara, an ophthalmologist and retina specialist with 25 years of experience in retinal imaging innovation. The discussion…
Nicox releases topline data from phase 3 Denali trial of NCX 470 in open-angle glaucoma or ocular hypertension patients
(Image Credit: AdobeStock/Naypong Studio) Nicox has announced that the phase 3 Denali trial of NCX 470 0.1% met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline in open-angle glaucoma or ocular hypertension patients compared to the…
FDA extends target action date for two Regeneron regulatory submissions to Q4 of 2025
(Image Credit: AdobeStock/Ascannio The US Food and Drug Administration (FDA) has extended the target action dates for Regeneron Pharmaceuticals’ 2 EYLEA HD (aflibercept) Injection 8 mg regulatory submissions to the fourth quarter of 2025. The 2 regulatory submissions include a Chemistry, Manufacturing,…
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients – GlobeNewswire
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients GlobeNewswire Source: Author: | Date: 2025-08-21 05:32:00 Source: Author: | Date: 2025-08-21 05:32:00
The risk of sight-threatening diabetic retinopathy with GLP-1 RA use
Andy J. Barkmeier, MD, an associate professor of ophthalmology and vitreoretinal surgery at Mayo Clinic in Rochester, Minnesota, presented findings on GLP-1 medications and their relationship to diabetic retinopathy complications at the 2025 ASRS meeting in Long Beach, California. He…
The emerging era of presbyopia-correcting eye drops: What’s next?
(Image Credit: AdobeStock/taffpixture) Since 2021, only 1 prescription eye drop for the correction of presbyopia, pilocarpine HCI ophthalmic solution 1.25% (Vuity; AbbVie), has been available, with additional options expected soon. In early 2025, a second eye drop, pilocarpine HCI ophthalmic…